Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms

Ding Chen, Monica Blazek, Sara Ireland, Sterling Ortega, Xiangmei Kong, Anouk Meeuwissen, Ann Stowe, Laura Carter, Yue Wang, Ronald Herbst, Nancy L. Monson

Neurology & Neurotherapeutics - NE Stroke Section
Neurology & Neurotherapeutics
Neurology & Neurotherapeutics - NE Multiple Sclerosis Section
Immunology

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Fingerprint

Dive into the research topics of 'Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms'. Together they form a unique fingerprint.

Sort by
Weight
Alphabetically

Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms

Fingerprint

Medicine & Life Sciences